Israel-based Taro Pharmaceutical posted a net profit growth of 42.3 percent year-on-year at USD 88.8 million for the third quarter of financial year 2012-13.
Net sales grew by 25.4 percent to USD 185.7 million from USD 148.1 million during the same period.
Operating margin improved by 570 basis points year-on-year to 56 percent in the October-December quarter.
Meanwhile, research and development cost jumped by 33.5 percent YoY to USD 11.8 million in the third quarter.
After this stellar performance by subsidiary, shares of Sun Pharmaceutical rallied 4.44 percent to Rs 750 on Bombay Stock Exchange at 9:29 hours IST.
Today the company said the USFDA has granted its subsidiary an approval for its abbreviated new drug application (ANDA) for generic version of Doxil. This injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.
Also Read
Zensar Tech eyeing acquisitions in USD 30-40 million space
Houseviews: 4 stocks for investors to keep their eye on
Bull's eye: Buy Escorts, Dabur, Jet Airways; short UCO Bank
Stocks in news: Nestle, United Spirits, Zee Learn, RCF
Anda sedang membaca artikel tentang
Sun Pharma surges 4% after Taro's excellent Q3 numbers
Dengan url
https://kesehatanda.blogspot.com/2013/02/sun-pharma-surges-4-after-taros.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Sun Pharma surges 4% after Taro's excellent Q3 numbers
namun jangan lupa untuk meletakkan link
Sun Pharma surges 4% after Taro's excellent Q3 numbers
sebagai sumbernya
0 komentar:
Posting Komentar